# Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

> **NCT06090786** · NA · NOT_YET_RECRUITING · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 225 (estimated)

## Conditions studied

- AML, Adult
- Minimal Residual Disease

## Interventions

- **DIAGNOSTIC_TEST:** MRD assessment

## Key facts

- **NCT ID:** NCT06090786
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 225 (ESTIMATED)
- **Last updated:** 2024-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06090786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06090786, "Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06090786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*